BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...kinase 1MEK2 (MAP2K2) – MAP kinase kinase 2ROCK2 - Rho-associated coiled-coil containing protein kinase 2 BC Staff NeuroRx Inc. BGI...
BioCentury | Feb 24, 2021
Product Development

Feb. 23 Quick Takes: Hold for bluebird; plus priority review for Pfizer’s TicoVac and updates from Taiho and NeuroRx

...an oral inhibitor of heat shock protein 90.NeuroRx has sights set on EUA for COVID treatment NeuroRx Inc....
...seen at 28 days read through to 60 days. BC Staff Taiho Pharmaceutical Co. Ltd. Pfizer Inc. bluebird bio Inc. NeuroRx...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 COVID Quick Takes: Actemra reduces mortality in RECOVERY trial; plus updates from AZ, CanSino, Celltrion, NeuroRx, CureVac and Moderna

...the total doses purchased to 600 million. Each company is delivering 300 million doses through July.NeuroRx...
...on preliminary data from the study, which was run with Relief Therapeutics Holding AG (SIX:RLF). NeuroRx...
...Generic), RoActemra (Informal), MRA (Informal), Actemra (Informal) Ad5-nCoV CT-P59 Aviptadil, Zyesami (RLF-100) Genentech Inc. Roche AstraZeneca plc University of Oxford CanSino Biologics Inc. Celltrion Inc. NeuroRx Inc. Relief...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Phase II testing for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis.NeuroRx...
...Management Biosion Inc. Lapam Capital Kaiyuan Capital Oceanpine Healthcare Fund Zheshang Innovest Shenzhen HighTide Biopharmaceutical Ltd. Greater Bay Area Homeland Development Fund Tigermed Citic Securities NeuroRx Inc. Alkermes...
BioCentury | Aug 6, 2020
Product Development

BioNTech testing separate mRNA vaccine variant in Chinese trial, closes supply deal with Canada

...by the end of 2021. Data for Relief, NeuroRx Relief Therapeutics Holding AG (SIX:RLF) and NeuroRx Inc....
...sensitivity and specificity. Elizabeth S. Eaton, Staff Writer and Sandi Wong, Assistant Editor Aviptadil (RLF-100) BNT162b1 BNT162b2 Relief Therapeutics Holding AG NeuroRx Inc. Clinical...
BioCentury | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

...GEM to provide NeuroRx with capital for Phase III trials Global Emerging Markets will provide NeuroRx Inc....
...to HK$750 million ($95.6 million) over 30 months following the mental illness company's public listing. NeuroRx...
...valued at $350.4 million. Elizabeth Eaton, Staff Writer and Paul Bonanos, Associate Editor Alexion Pharmaceuticals Inc. RAPT Therapeutics Inc. NeuroRx Inc. Oyster...
BioCentury | Jan 11, 2019
Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

...from baseline to day 14 by 11 points vs. standard of care (SOC) lurasidone (p=0.03). NeuroRx...
...U.S. trial received NRX-101 or lurasidone after stabilization with a single IV infusion of ketamine. NeuroRx...
...D-cycloserine, a glycine site NMDA receptor antagonist, and lurasidone, a small molecule antagonist of 5-HT2A. NeuroRx Inc....
BioCentury | Jan 5, 2017
Clinical News

NRX-101: Ph IIb/III started

...vs. Latuda lurasidone for up to 6 weeks in about 120 patients with bipolar depression. NeuroRx Inc....
...suicidality; measures of depression on series of psychometric scales Status: Phase IIb/III started Milestone: NA Julian Zhu Cyclurad NeuroRx Inc. NMDA...
BioCentury | Mar 20, 2014
Tools & Techniques

Plasma lipids: harbingers of AD?

...2014; doi:10.1038/nm.3466 Contact: Howard J. Federoff, Georgetown University, Washington, D.C. e-mail: hjf8@georgetown.edu 2. Irizarry, M.C. NeuroRx...
BioCentury | Nov 13, 2008
Tools & Techniques

ArmaGen's gatecrashers

...110-124 (1998) 10. Doolittle, N. et al. Cancer 88 , 637-647 (2000) 11. Shusta, E. NeuroRx...
Items per page:
1 - 10 of 11
BioCentury | Feb 24, 2021
Deals

Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa

...kinase 1MEK2 (MAP2K2) – MAP kinase kinase 2ROCK2 - Rho-associated coiled-coil containing protein kinase 2 BC Staff NeuroRx Inc. BGI...
BioCentury | Feb 24, 2021
Product Development

Feb. 23 Quick Takes: Hold for bluebird; plus priority review for Pfizer’s TicoVac and updates from Taiho and NeuroRx

...an oral inhibitor of heat shock protein 90.NeuroRx has sights set on EUA for COVID treatment NeuroRx Inc....
...seen at 28 days read through to 60 days. BC Staff Taiho Pharmaceutical Co. Ltd. Pfizer Inc. bluebird bio Inc. NeuroRx...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 COVID Quick Takes: Actemra reduces mortality in RECOVERY trial; plus updates from AZ, CanSino, Celltrion, NeuroRx, CureVac and Moderna

...the total doses purchased to 600 million. Each company is delivering 300 million doses through July.NeuroRx...
...on preliminary data from the study, which was run with Relief Therapeutics Holding AG (SIX:RLF). NeuroRx...
...Generic), RoActemra (Informal), MRA (Informal), Actemra (Informal) Ad5-nCoV CT-P59 Aviptadil, Zyesami (RLF-100) Genentech Inc. Roche AstraZeneca plc University of Oxford CanSino Biologics Inc. Celltrion Inc. NeuroRx Inc. Relief...
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...Phase II testing for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis.NeuroRx...
...Management Biosion Inc. Lapam Capital Kaiyuan Capital Oceanpine Healthcare Fund Zheshang Innovest Shenzhen HighTide Biopharmaceutical Ltd. Greater Bay Area Homeland Development Fund Tigermed Citic Securities NeuroRx Inc. Alkermes...
BioCentury | Aug 6, 2020
Product Development

BioNTech testing separate mRNA vaccine variant in Chinese trial, closes supply deal with Canada

...by the end of 2021. Data for Relief, NeuroRx Relief Therapeutics Holding AG (SIX:RLF) and NeuroRx Inc....
...sensitivity and specificity. Elizabeth S. Eaton, Staff Writer and Sandi Wong, Assistant Editor Aviptadil (RLF-100) BNT162b1 BNT162b2 Relief Therapeutics Holding AG NeuroRx Inc. Clinical...
BioCentury | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

...GEM to provide NeuroRx with capital for Phase III trials Global Emerging Markets will provide NeuroRx Inc....
...to HK$750 million ($95.6 million) over 30 months following the mental illness company's public listing. NeuroRx...
...valued at $350.4 million. Elizabeth Eaton, Staff Writer and Paul Bonanos, Associate Editor Alexion Pharmaceuticals Inc. RAPT Therapeutics Inc. NeuroRx Inc. Oyster...
BioCentury | Jan 11, 2019
Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

...from baseline to day 14 by 11 points vs. standard of care (SOC) lurasidone (p=0.03). NeuroRx...
...U.S. trial received NRX-101 or lurasidone after stabilization with a single IV infusion of ketamine. NeuroRx...
...D-cycloserine, a glycine site NMDA receptor antagonist, and lurasidone, a small molecule antagonist of 5-HT2A. NeuroRx Inc....
BioCentury | Jan 5, 2017
Clinical News

NRX-101: Ph IIb/III started

...vs. Latuda lurasidone for up to 6 weeks in about 120 patients with bipolar depression. NeuroRx Inc....
...suicidality; measures of depression on series of psychometric scales Status: Phase IIb/III started Milestone: NA Julian Zhu Cyclurad NeuroRx Inc. NMDA...
BioCentury | Mar 20, 2014
Tools & Techniques

Plasma lipids: harbingers of AD?

...2014; doi:10.1038/nm.3466 Contact: Howard J. Federoff, Georgetown University, Washington, D.C. e-mail: hjf8@georgetown.edu 2. Irizarry, M.C. NeuroRx...
BioCentury | Nov 13, 2008
Tools & Techniques

ArmaGen's gatecrashers

...110-124 (1998) 10. Doolittle, N. et al. Cancer 88 , 637-647 (2000) 11. Shusta, E. NeuroRx...
Items per page:
1 - 10 of 11